Piper Sandler maintains Corcept Therapeutics at Overweight, raises price target to $173 from $165
Piper Sandler kept its Overweight rating on Corcept Therapeutics and increased its price target to $173 from $165, suggesting a 111.2% upside from the Nov 3 close of $81.93, according to the firm.
How this was made

The 30-second read
Why it matters
The price‑target raise may trigger short‑covering and new buying, but actual stock movement depends on upcoming clinical data.
Market read
Analyst upgrade provides a fresh catalyst for a small‑cap biotech, offering a modest trading opportunity.
What to watch
Potential regulatory or trial setbacks not reflected in the target.
Background
Corcept Therapeutics is a biotech focused on cortisol‑related therapies; analyst coverage is sparse.
Market effects
May lift sentiment in the biotech sector as analysts show confidence in Corcept's pipeline.
Limited to U.S. biotech investors.
Minimal global impact.
Counterpoint
The target increase could be premature if upcoming trial data disappoints.
Key entities
- Analyst FirmPiper Sandler
Issued the upgraded price target.
- CompanyCorcept Therapeutics
Biotech firm receiving the upgraded target.

